|
Formulation of Product |
|||
| Dose Groups |
Peptides loaded / HLA class |
Peptide loading method and concentration |
DEX dose (expressed as numbers of MHC class II molecules) |
|
|
|||
| A |
MAGE A3 (168–176) / class I |
Indirect (10 μg/mL) |
0.13 × 1014 |
| MAGE A3 (247–258) / class II |
Indirect (10 μg/mL) |
||
| tetanus toxoid / class II |
Indirect (10 μg/mL) |
||
| B |
MAGE A3 (168–176) / class I |
Indirect (10 μg/mL) |
0.4 × 1014 |
| MAGE A3 (247–258) / class II |
Indirect (10 μg/mL) |
||
| C |
MAGE A3 (168–176) / class I |
Direct (10 μg/mL) |
0.13 × 1014 |
| MAGE A3 (247–258) / class II |
Indirect (10 μg/mL) |
||
| tetanus toxoid / class II |
Indirect (10 μg/mL) |
||
| D |
MAGE A3 (168–176) / class I |
Direct (100 μg/mL) |
0.13 × 1014 |
| MAGE A3 (247–258) / class II |
Indirect (10 μg/mL) |
||
Escudier et al. Journal of Translational Medicine 2005 3:10 doi:10.1186/1479-5876-3-10 |
|||